Baylor-UTHouston Center for AIDS Research

贝勒-休斯顿大学艾滋病研究中心

• 批准号: 7278570
• 负责人: JANET S BUTEL
• 金额: $ 151.59万
• 依托单位: BAYLOR COLLEGE OF MEDICINE
• 依托单位国家: 美国
• 财政年份: 1997
• 资助国家: 美国
• 起止时间: 1997-04-01 至 2010-07-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7278570
• 关键词: AIDS/HIV problem; Acquired Immunodeficiency Syndrome; Address; Adult; Advisory Committees; Area; Behavioral; Behavioral Sciences; Botswana; Clinical; Clinical Research; Collaborations; Communication; Community Outreach; Detection; Developed Countries; Developing Countries; Development; Disadvantaged; Doctor of Medicine; Doctor of Philosophy; Environment; Faculty; Fostering; Funding; Goals; Grant; HIV; HIV Infections; Health Sciences; Immunology; Industry; Institution; International; Knowledge; Leadership; Medical center; Mentors; Minority; Mission; Modification; Mycobacterium tuberculosis; Policies; Policy Making; Population; Prevention; Procedures; Process; Published Comment; Reapplication; Request for Applications; Research; Research Activity; Research Infrastructure; Review Committee; Romania; Rural; Services; Site; Strategic Planning; Support of Research; Sustainable Development; Targeted Research; Technology Transfer; Texas; Training and Education; Translational Research; United States National Institutes of Health; Universities; base; decision research; design; inner city; innovation; multidisciplinary; novel; novel strategies; programs; virology

DESCRIPTION (provided by applicant): This revised application requests renewal of the Baylor-UT Houston Center for AIDS Research (CFAR), formerly the Baylor CFAR. This reflects the new partnership of Baylor with The University of Texas Health Science Center at Houston (UT Houston), both located in the Texas Medical Center in Houston. Both institutions strongly endorse this partnership, and in the year since the previous application, the Baylor and UTHouston components of the CFAR have been successfully integrated. The partnership broadens the HIV/AIDS research programs and opportunities for translational research in the CFAR by adding UT Houston programs in adult HIV/AIDS clinical studies and in the behavioral sciences to Baylor's existing strengths. Our combined NIH Funded Research Base for FY2003 totals $21.9 million. We used a comprehensive strategic planning process to address reviewer comments. We obtained advice from NIH CFAR program officials and our External Advisors and conducted a thorough revaluation of each CFAR core. This resulted in major reorganizations and modifications in the goals, functions, and/or services provided by the Clinical Research, Behavioral Science, and International Research Cores. Other scientific cores (Immunology, Virology, Design and Analysis) are also revised. Cores are now more innovative and focused on CFAR goals. New approaches were designed to use Developmental Core funds in novel ways to foster translational research. Strategies include targeting research activities that fill gaps, take advantage of opportunities in the CFAR, and encourage interactions between institutions and synergy among CFAR Cores. A Scientific Program will be supported in HIV and Coinfections, focusing on HIV and Mycobacterium tuberculosis, areas of expertise at our CFAR. Several of these new research programs utilize the infrastructure at Baylor's international sites in Romania and Botswana. We believe these changes result in a more visionary, proactive CFAR. A comprehensive mentoring program for junior faculty in HIV/AIDS research is new to this reapplication. The CFAR is led by Janet S. Butel, Ph.D. (Director), William T. Shearer, M.D., Ph.D. (Co-Director), and Richard M. Grimes, Ph.D. (Associate Director and Liaison to UTHouston). CFAR decisions and actions are guided by a set of Policies and Procedures and an annual Strategic Planning Process. The major policy-making body of the CFAR is the Internal Advisory Committee; management is assisted by External Advisory and Developmental Grants Scientific Review Committees.

描述（由申请人提供）：本修订后的申请要求续签贝勒-UT 休斯顿艾滋病研究中心 (CFAR)（以前称为贝勒 CFAR）。这反映了贝勒与德克萨斯大学休斯顿健康科学中心（UT休斯顿）的新合作伙伴关系，两者均位于休斯顿的德克萨斯医学中心。两家机构都强烈支持这一合作伙伴关系，自上次申请以来的一年内，CFAR 的贝勒和UTHouston 部分已成功整合。该合作伙伴关系通过将德克萨斯大学休斯敦分校在成人艾滋病毒/艾滋病临床研究和行为科学方面的项目添加到贝勒现有的优势中，扩大了 CFAR 中的艾滋病毒/艾滋病研究项目和转化研究的机会。 2003 财年 NIH 资助的研究基地总计 2190 万美元。我们使用了全面的战略规划流程来解决审稿人的意见。我们听取了 NIH CFAR 项目官员和外部顾问的建议，并对每个 CFAR 核心进行了彻底的重新评估。这导致临床研究、行为科学和国际研究核心提供的目标、职能和/或服务发生重大重组和修改。其他科学核心（免疫学、病毒学、设计和分析）也进行了修订。核心现在更具创新性并专注于 CFAR 目标。新方法旨在以新颖的方式使用发展核心资金来促进转化研究。策略包括开展旨在填补空白、利用 CFAR 机会并鼓励机构之间互动和 CFAR 核心之间协同作用的研究活动。我们将在艾滋病毒和合并感染领域支持一项科学计划，重点关注艾滋病毒和结核分枝杆菌，这是我们 CFAR 的专业领域。其中一些新的研究项目利用了贝勒在罗马尼亚和博茨瓦纳的国际基地的基础设施。我们相信这些变化会带来更有远见、更主动的恒虚警。针对艾滋病毒/艾滋病研究初级教师的综合指导计划是此次重新申请的新内容。 CFAR 由 Janet S. Butel 博士领导。 （主任），William T. Shearer，医学博士、哲学博士（联合主任）和 Richard M. Grimes 博士（副主任兼UT休斯顿大学联络员）。 CFAR 的决策和行动以一套政策和程序以及年度战略规划流程为指导。 CFAR的主要决策机构是内部咨询委员会；管理由外部咨询和发展补助金科学审查委员会协助。